A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

Blood Cancer J. 2025 Jun 17;15(1):109. doi: 10.1038/s41408-025-01296-8.

Chandramouli Nagarajan^#^{1

2}, Wei-Ying Jen^#^{3

4}, Melissa Ooi³, Sanjay De Mel³, Cinnie Soekojo³, Sung Soo Yoon⁵, Melinda Tan^{1

2}, Yunxin Chen^{1

2}, Xinhua Li⁶, Yogesh Pokharkar⁶, Shi Ning Tham¹, Nur Shahidah Binte Hashim¹, Neha Awasthi⁶, Sarah M Burkill⁶, Brian Durie⁷, Wee Joo Chng^{8

9}

¹ Department of Haematology, Singapore General Hospital, Singapore, Singapore.
² Duke-NUS Medical School, Singapore, Singapore.
³ Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
⁴ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁵ Seoul National University Hospital, Seoul, South Korea.
⁶ Singapore Clinical Research Institute, Singapore, Singapore.
⁷ Cedars-Sinai Medical Center, Los Angeles, USA.
⁸ Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg.
⁹ Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. mdccwj@nus.edu.sg.

^# Contributed equally.

Abstract